Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

1.33
-0.0400-2.92%
Post-market: 1.330.00000.00%17:09 EDT
Volume:2.16M
Turnover:3.00M
Market Cap:152.41M
PE:-0.81
High:1.49
Open:1.42
Low:1.33
Close:1.37
Loading ...

Fate Therapeutics upgraded to Neutral from Underperform at BofA

TIPRANKS
·
19 Nov 2024

Fate Therapeutics Hold Rating: Promising Early Results Amidst Developmental Challenges

TIPRANKS
·
19 Nov 2024

Stifel ‘impressed’ with results for Fate Therapeutics’ first FT819 LN patient

TIPRANKS
·
19 Nov 2024

Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results

MT Newswires Live
·
19 Nov 2024

Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial

TIPRANKS
·
18 Nov 2024

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

GlobeNewswire
·
18 Nov 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

GlobeNewswire
·
18 Nov 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Simply Wall St.
·
15 Nov 2024

Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
14 Nov 2024

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)

TIPRANKS
·
14 Nov 2024

Cautious Hold Rating for Fate Therapeutics Amidst Clinical Uncertainties and Financial Stability

TIPRANKS
·
14 Nov 2024

Fate Therapeutics’ Stock Volatility: Impact of Partnerships and Regulatory Challenges

TIPRANKS
·
14 Nov 2024

Fate Therapeutics Unveils Q3 2024 Financial Highlights

TIPRANKS
·
14 Nov 2024

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

Zacks
·
14 Nov 2024

Fate Therapeutics (FATE) Receives a Buy from Piper Sandler

TIPRANKS
·
13 Nov 2024

Conservative Hold Rating for Fate Therapeutics Amid Early Pipeline Development and Unclear Competitive Edge

TIPRANKS
·
13 Nov 2024

Hold Rating Maintained for Fate Therapeutics Amid Early Development Stage and Financial Stability

TIPRANKS
·
13 Nov 2024

Fate Therapeutics (FATE) Receives a Buy from Barclays

TIPRANKS
·
13 Nov 2024

U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot

Reuters
·
13 Nov 2024

TD Cowen Sticks to Its Hold Rating for Fate Therapeutics (FATE)

TIPRANKS
·
13 Nov 2024